UNILEAD

UniLead Biotech is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer immunotherapies. The company specializes in targeting the CD47-SIRPα signaling pathway, a key immune checkpoint that cancer cells exploit to avoid phagocytosis by macrophages. UniLead's lead program, ULB101, is a high-affinity anti-CD47 monoclonal antibody engineered to maintain potent anti-tumor activity while significantly reducing the risk of anemia and hemagglutination associated with first-generation CD47 inhibitors. By optimizing the safety profile of these inhibitors, the company aims to expand the therapeutic window for CD47-targeted treatments. The company is currently advancing its pipeline through clinical trials to address unmet needs in various solid tumors and hematological cancers. UniLead leverages its expertise in antibody engineering to create differentiated biologics with improved clinical outcomes.